- Home
- TEN vs AURA Comparison
TEN vs AURA Comparison
Compare TEN & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEN
- AURA
- Stock Information
- Founded
- TEN 1993
- AURA 2007
- Country
- TEN Greece
- AURA United States
- Employees
- TEN N/A
- AURA N/A
- Industry
- TEN
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- TEN
- AURA Health Care
- Exchange
- TEN NYSE
- AURA Nasdaq
- Market Cap
- TEN 531.7M
- AURA 438.3M
- IPO Year
- TEN N/A
- AURA 2021
- Fundamental
- Price
- TEN $16.91
- AURA $8.37
- Analyst Decision
- TEN Buy
- AURA Strong Buy
- Analyst Count
- TEN 2
- AURA 4
- Target Price
- TEN $31.00
- AURA $23.00
- AVG Volume (30 Days)
- TEN 430.9K
- AURA 211.1K
- Earning Date
- TEN 11-26-2024
- AURA 11-12-2024
- Dividend Yield
- TEN 11.03%
- AURA N/A
- EPS Growth
- TEN N/A
- AURA N/A
- EPS
- TEN 5.46
- AURA N/A
- Revenue
- TEN $836,042,000.00
- AURA N/A
- Revenue This Year
- TEN N/A
- AURA N/A
- Revenue Next Year
- TEN $10.35
- AURA N/A
- P/E Ratio
- TEN $3.02
- AURA N/A
- Revenue Growth
- TEN N/A
- AURA N/A
- 52 Week Low
- TEN $15.88
- AURA $6.63
- 52 Week High
- TEN $31.48
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- TEN 26.60
- AURA 42.50
- Support Level
- TEN $15.88
- AURA $8.30
- Resistance Level
- TEN $19.16
- AURA $9.04
- Average True Range (ATR)
- TEN 0.64
- AURA 0.43
- MACD
- TEN -0.06
- AURA 0.03
- Stochastic Oscillator
- TEN 24.39
- AURA 24.81
About TEN TSAKOS ENERGY NAVIGATION
Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.